Foghorn Therapeutics Inc. announced that Chief Financial Officer, Allan Reine will be departing the Company to pursue another opportunity. The company has commenced a formal search for a successor. Dr. Reine?s last day as a full-time employee with Foghorn will be January 16, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.22 USD | 0.00% | +17.58% | -3.57% |
May. 20 | Foghorn Therapeutics Prices $110 Million Offering of Shares, Pre-Funded Warrants | MT |
May. 06 | Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.57% | 344M | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.70% | 21.97B | |
-4.64% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- FHTX Stock
- News Foghorn Therapeutics Inc.
- Foghorn Therapeutics Inc. Announces Resignation of Allan Reine as Chief Financial Officer, Effective January 16, 2024